BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

CAPS Rating: 1 out of 5

A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.

Results 21 - 36 of 36 : « Previous 1 2

Recs

0
Member Avatar scbeachbum (63.03) Submitted: 2/11/2008 12:03:25 PM : Outperform Start Price: $3.87 BCRX Score: -19.09

With bird flu season around the corner, news should pick back up on it and more of a focus will be made on the companies in that sector. BCRX is beaten down to the point it makes a good potential acquisition candidate too.

Recs

0
Member Avatar ciation1 (20.65) Submitted: 8/14/2007 3:35:04 PM : Outperform Start Price: $9.96 BCRX Score: -64.37

Over sold, improving technicals, fundamentals.

Recs

0
Member Avatar tharlow (31.04) Submitted: 8/11/2007 4:33:25 PM : Outperform Start Price: $9.62 BCRX Score: -61.03

Clear leader in bird flu technologies.

Recs

1
Member Avatar iknowhow2trade (< 20) Submitted: 6/4/2007 9:50:01 PM : Outperform Start Price: $8.05 BCRX Score: -50.35

over sold great speculation

Recs

1
Member Avatar NelsonLai1975 (< 20) Submitted: 5/11/2007 10:41:46 AM : Outperform Start Price: $7.92 BCRX Score: -51.84

Only waiting for
1. Paramarvir to go GA
2. Bird Flu hit US.

After that, will take profits

Recs

1
Member Avatar willem1955 (< 20) Submitted: 4/20/2007 1:34:11 AM : Outperform Start Price: $9.47 BCRX Score: -59.80

breakthrough medication if birdflu breaks out

Recs

2
Member Avatar acecannon (91.85) Submitted: 4/18/2007 3:03:23 PM : Underperform Start Price: $9.58 BCRX Score: +60.75

It's not a matter of if, but when, the stock goes to 0. My pick is for an outbreak of 0 in Asia first, followed by Canada, then lastly America.

Recs

0
Member Avatar PairODeuces (45.20) Submitted: 1/11/2007 8:11:01 PM : Outperform Start Price: $10.88 BCRX Score: -68.70

Several promising products in pipe. Recent government funding for Peramavir, like Tamiflu but better. Possible M or A target.

Recs

0
Member Avatar beardless1 (22.51) Submitted: 12/27/2006 6:01:33 PM : Outperform Start Price: $11.98 BCRX Score: -71.25

New products coming, plus it will rise if avian flu concerns increase.

Recs

0
Member Avatar ToogleBH (89.89) Submitted: 11/26/2006 1:50:24 AM : Outperform Start Price: $11.78 BCRX Score: -72.33

Biotech company developing drugs that block key enzymes involved in cancer, heart diseases, autoimmune diseases, and viral infections

Recs

3
Member Avatar robincam (< 20) Submitted: 11/17/2006 10:28:25 PM : Outperform Start Price: $11.91 BCRX Score: -72.73

lets put it this way its not a matter of if but when the avian flu will come to america in the human population.asia will be first i,m predicting this year will get the first big outbreak. if i was you i,d buy some tami flu like now.

Recs

0
Member Avatar rxdan (20.90) Submitted: 10/17/2006 2:31:46 PM : Outperform Start Price: $11.78 BCRX Score: -75.66

Bird Flu drug

Recs

0
Member Avatar loubfool (37.68) Submitted: 9/29/2006 11:35:53 PM : Outperform Start Price: $12.50 BCRX Score: -78.94

whose chicken ?

Recs

1
Member Avatar mansloth (97.26) Submitted: 9/11/2006 9:38:38 AM : Underperform Start Price: $9.75 BCRX Score: +75.01

If I could short rational drug design I would. But I can't, so this will have to do in the meantime.

Don't get me wrong. I'm all for solving structures and playing with the active site. But with this sort of strategy I think the odds of success are better if you play the lottery.

So, based on my bias against rationally-designed drugs as good investments, this short pick is my bet that fodosine will yield lackluster clinical results.

Recs

1
Member Avatar bonedoc100 (< 20) Submitted: 8/27/2006 12:28:45 AM : Outperform Start Price: $9.59 BCRX Score: -74.61

killed by cramer

Recs

3
Member Avatar rthambu (< 20) Submitted: 8/18/2006 7:03:21 PM : Outperform Start Price: $9.01 BCRX Score: -71.92

Biocryst (BRCX) pharma is a small biopharmaceutical company that has already established a name in the antivirals segment, especially with their leading bird-flu vaccination. Although this is a volatile stock, i predict this company to either partner or be bought out by other giants such as Roche or Astra Zeneca; The valuation is fair and the stock has dropped about 50% since the beginning of this year. So a good time to buy this aggressive growth stock.

Results 21 - 36 of 36 : « Previous 1 2

Featured Broker Partners


Advertisement